Pre-Made Atacicept Biosimilar, Fusion Protein targeting TNFSF13/APRIL fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting CD256/TALL-2/TALL2/TNLG7B/TRDL-1/UNQ383/PRO715/ZTNF2 for drug discovery and mechanism of action (MOA) research

Pre-Made Atacicept Biosimilar, Fusion Protein targeting TNFSF13/APRIL fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting CD256/TALL-2/TALL2/TNLG7B/TRDL-1/UNQ383/PRO715/ZTNF2 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Atacicept is a recombinant fusion protein designed to inhibit B cells, thereby suppressing autoimmune disease. The designer protein combines the binding site for two cytokines that regulate maturation, function, and survival of B cells – B-lymphocyte stimulator (BLyS) and A proliferation-inducing ligand (APRIL), with the constant region of immunoglobin.[1] Atacicept blocks activation of B cells by the tumor necrosis factor receptor superfamily member 13B (more commonly known as TACI), a transmembrane receptor protein found predominantly on the surface of B cells. Like the monoclonal antibody belimumab, atacicept blocks the binding of BLyS, but it also blocks APRIL. Binding of these TACI ligands induces proliferation, activation, and longevity of B cells and thus their production of autoantibodies.[2] Atacicept is thought to selectively impair mature B cells and plasma cells with less impact on progenitor cells and memory B cells.[3]

Atacicept is a recombinant fusion protein designed to inhibit B cells, thereby suppressing autoimmune disease. Atacicept is a fully human recombinant fusion protein consisting of the Fc region of human IgG1 and the binding portion of transmembrane activator and CAML interactor (TACI; also known as tumor necrosis factor receptor superfamily member 13B), which is able to bind the cytokines B cell-activating factor (BAFF; also termed B-lymphocyte stimulator or BlyS) and a proliferation-inducing ligand (APRIL). Atacicept blocks activation of B cells by the tumor necrosis factor receptor superfamily member 13B (more commonly known as TACI), a transmembrane receptor protein found predominantly on the surface of B cells. Atacicept blocks the binding of BLyS, but it also blocks APRIL. Atacicept is thought to selectively impair mature B cells and plasma cells with less impact on progenitor cells and memory B cells.